Oral Treosulfan as Second-Line Treatment in Platinum-Resistant Ovarian Cancer: A Phase II Study

By Keldsen N.   Madsen E.L.   Havsteen H.   Kamby C.   Laursen L.   Sandberg E.   on behalf of The Danish Ovarian Cancer Study Group  

Gynecologic Oncology, Vol. 69, Iss. 2, 1998-05 ,pp. : 100-102

Elsevier

Access to resources Recommend Favorite

Paclitaxel vs Epidoxorubicin plus Paclitaxel as Second-Line Therapy for Platinum-Refractory and -Resistant Ovarian Cancer

By Bolis G.   Parazzini F.   Scarfone G.   Villa A.   Amoroso M.   Rabaiotti E.   Polatti A.   Reina S.   Pirletti E.  

Gynecologic Oncology, Vol. 72, Iss. 1, 1999-01 ,pp. : 60-64

Elsevier

Access to resources Recommend Favorite

Taxol as Second-Line Treatment in Patients with Advanced Ovarian Cancer after Platinum-Based First-Line Chemotherapy

By Mayerhofer K.   Kucera E.   Zeisler H.   Speiser P.   Reinthaller A.   Sevelda P.  

Gynecologic Oncology, Vol. 64, Iss. 1, 1997-01 ,pp. : 109-113

Elsevier

Access to resources Recommend Favorite

Altretamine (Hexamethylmelamine) in Platinum-Resistant and Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Phase II Trial

By Markman M.   Blessing J.A.   Moore D.   Ball H.   Lentz S.S.  

Gynecologic Oncology, Vol. 69, Iss. 3, 1998-06 ,pp. : 226-229

Elsevier

Access to resources Recommend Favorite

Second-Line Therapy for Potentially Platinum-Sensitive Recurrent Ovarian Cancer: What Is Optimal Treatment?

By Markman M.  

Gynecologic Oncology, Vol. 81, Iss. 1, 2001-04 ,pp. : 1-2

Elsevier

Access to resources Recommend Favorite